Ethoheptazine
Clinical data | |
---|---|
Trade names | Equagesic |
Other names | Zactane |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Ethoheptazine[1] (trade name Zactane) is an opioid analgesic from the phenazepane family. It was invented in the 1950s[2] and is a ring expanded analogue of pethidine.[3]
Ethoheptazine produces similar effects to other opioids, including
It is no longer prescribed, as it is no longer FDA approved, and not available for United States' Pharmacy Processing. Revocation of FDA Approved Medications Status stems from a combination of efficacy vs. toxicity, and the more-varied and historically safer Benzodiazepines Class. Only reversal of the FDA's decision, allows removing the drug from the CSD. Ethoheptazine is not listed as a controlled substance under the Controlled Substances Act, 1970 in the United States.[7] The controlled status (Schedule IV) of Equagesic was due to the meprobamate content.[8][7] Regulation elsewhere varies.
References
- ^ ES 310184, "Procedure for the preparation of a new derivative of pirazolidine-hexametilenimina with therapeutic properties."
- S2CID 32299049.
- PMID 14186026.
- PMID 13879557.
- PMID 4214668.
- PMID 41087.
- ^ a b "Conversion Factors for Controlled Substances". Diversion Control Division. Drug Enforcement Agency, U.S. Department of Justice. Archived from the original on 2016-03-02. Retrieved 2016-02-27.
- ^ PDR 1978, pp 1618